Table 2.

Treatment-Related Outcomes and Change in CA19-9 Levels From Baseline With 95% Confidence Interval and P Value

CA19-9 Change from Baseline to Cycle 2	mOS (mo)	95% CI	N	P	mTTP (mo)	95% CI	n	P
≥75% Decline	11.2	5.4–21.1	17	.034	7.5	3.7–11.5	17	.12
<75% Decline	8.5	7.2–10.2	87		5.4	4.2–7.7	81
≥50% Decline	10.7	8.7–13.2	44	.049	7.7	7–9.6	43	.026
<50% Decline	7.6	5.2–8.9	60		4.3	3.3–6	55
≥25% Decline	10.4	8.8–13	58	.003	7.5	6.3–8.8	55	.028
<25% Decline	7	4.8–8.9	46		4.3	3.1–5.4	43
>0% Decline	10.3	8.8–11.5	73	.002	7.5	6.3–8.4	69	.0028
≤0% Decline	5.1	4.2–7.4	31		3.7	2.6–8.4	29
<5% Increase	10.3	8.8–11.3	76	.002	7.6	6.4–8.4	72	.0006
≥5% Increase	5.1	3.7–7	28		3.5	2–4.3	26

Abbreviations: CI, confidence interval; mOS, median overall survival; TTP, time to progression.